Data as of Dec 06
| +1.79 / +5.04%|
The 6 analysts offering 12-month price forecasts for Theravance Inc have a median target of 48.50, with a high estimate of 52.00 and a low estimate of 38.00. The median estimate represents a +29.89% increase from the last price of 37.34.
The current consensus among 8 polled investment analysts is to Buy stock in Theravance Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.